Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Evommune’s goal is to drive meaningful advances for patients by targeting inflammation at the source, to not only address symptoms but avoid disease progression.
Evommune's goal is to develop accessible innovations that address not only the symptoms of chronic inflammatory disease, but also halt disease progression, helping to prevent further medical complications in the future. We’re committed to evolving immunology, with a pipeline that includes programs specifically targeted to address highly prevalent inflammatory diseases demonstrating clear, unmet needs.
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. That’s why Evommune is here. Evommune’s pipeline includes programs designed to address highly prevalent inflammatory diseases where current therapies have limitations. Evommune’s goal is to drive meaningful advances for patients by targeting inflammation at the source, to not only address symptoms but avoid disease progression.
We use leading edge science to target the root causes of inflammation.
We are building a broad portfolio with best-in-class potential.
We have brought together the right team, with the right experience, at the right time.
Gregory S. Moss, Esq., Chief Corporate Strategy and Legal Officer at Evommune, a company advancing therapies for chronic inflammatory diseases, shares his insights on these life-threatening conditions.
Evommune, led by CEO Luis Peña, is on a mission of tackle one of the world’s leading root cause of deaths: chronic inflammation, which is linked to more than 100 autoimmune diseases.
Evommune founder Luis Peña expertise spans a spectrum of life science companies. He co-founded Dermira, was Senior Vice President of Portfolio Planning and Management at Stiefel, and held key roles at Connetics, Theravance and Genentech.
Evommune, Inc., a clinical-stage biotech and Cure Collaboration Residency company, secured $115 million in Series C financing, underscoring its pioneering approach to developing novel therapies for chronic inflammatory diseases.
